Scientists exploit leaks in blood brain barrier to treat glioblastoma

November 6, 2017, Cancer Research UK

An ovarian cancer drug can leak through the blood brain barrier to reach brain tumours and could be an effective treatment for glioblastoma, suggest results presented at the National Cancer Research Institute's (NCRI) Cancer Conference in Liverpool, today (Monday).

The Cancer Research UK-funded OPARATIC trial, which was managed by the charity's Centre for Drug Development, tested whether the ovarian cancer drug olaparib could reach glioblastoma, a type of tumour which is very difficult to treat. And early results show it successfully reaches at high enough levels for treatment.

The successful delivery of this drug is an important step as many others have failed to reach the tumour.

The study recruited 48 patients with glioblastoma which had returned after initial treatment. The majority of patients were then given olaparib in combination with the chemotherapy drug temozolomide.

Scientists looked at tumour samples and found that the drug penetrates the core of the as well as the surrounding areas which contain smaller numbers of cancerous cells. Cancer cells in these regions cannot be removed by surgery so reaching them with drugs is crucial.

The researchers also identified a way to safely combine both drugs by giving olaparib intermittently, minimising dangerous side effects.

Olaparib is a PARP inhibitor, which is already used to treat certain ovarian cancer patients and prevents damaged from repairing themselves after chemotherapy or radiotherapy.

The OPARATIC trial has paved the way for two additional clinical trials – PARADIGM and PARADIGM-2 – testing olaparib in combination with radiotherapy and temozolomide in patients with newly diagnosed glioblastoma.

Professor Anthony Chalmers, lead researcher and Chair of Clinical Oncology at the University of Glasgow, said: "Brain tumours are stubbornly difficult to treat and one of the main reasons for this is the blood brain barrier, a natural filter that blocks the passage of drugs.

"But these results suggest that olaparib is able to leak through because this barrier is disrupted in glioblastoma. By showing that this reaches brain tumours, we are in a much stronger position to use it to make current treatments more effective."

Dr Nigel Blackburn, Cancer Research UK's director of , said: "While overall survival for cancer is improving, survival for brain tumours is still very low and the is a significant pharmacological obstacle.

"Experimental trials like this, which test new ways to reach these hard to treat tumours, are crucially important if we are to see more patients survive their cancer."

Professor Susan Short, member of NCRI's Radiotherapy Research Working Group, said: "We're just beginning to realise the full potential of PARP inhibitors to tackle many different types of , so it's exciting to see that olaparib could potentially be used to treat glioblastoma in combination with chemotherapy and radiotherapy.

"These results are a huge step forwards in developing better treatments for patients with brain tumours, which claim too many lives every year."

Explore further: Pancreatic cancer trial to make tumours more sensitive to treatment

Related Stories

Pancreatic cancer trial to make tumours more sensitive to treatment

August 30, 2016
Cancer Research UK (CRUK) launches a first-of-its-kind pancreatic cancer clinical trial to make cancer cells more responsive to chemotherapy and radiotherapy, with University of Glasgow researcher Professor Jeff Evans as ...

Potential treatment for brain cancer as drug shrinks tumours

August 14, 2017
An international team of researchers has found a drug previously approved to treat breast cancer could also be used to shrink medulloblastoma, a common form of childhood brain tumour.

Brain tumors share common tricks to survive

October 25, 2017
Different types of brain tumours may use strikingly similar approaches to generate and use energy to survive in the brain, according to a new study published in PLOS ONE today.

Revamped drug may overcome resistance in brain tumours

January 14, 2015
Cancer Research UK scientists have taken steps to overcome drug resistance in glioblastoma, the most common type of brain tumour in adults, according to research published in Molecular Cancer Therapeutics.

BRCA-targeting drugs could treat prostate cancer, leading expert says

November 5, 2014
A pioneering cancer drug set to become the first to be approved specifically for inherited cancers could also be used much more widely to treat prostate cancer, a world-leading expert said today.

Giving chemotherapy after radiotherapy improves survival for patients with rare brain tumour

June 3, 2016
GIVING chemotherapy after radiotherapy delays further growth of a rare type of brain tumour, increasing the number of patients alive at five years from 44 per cent to 56 per cent.

Recommended for you

Scientists to improve cancer treatment effectiveness

October 19, 2018
Together with researchers from the University of Nantes and the University of Reims Champagne-Ardenne in France, experts from the National Research Nuclear University MEPhI have recently developed a quantum dot-based microarray ...

Why some cancers affect only young women

October 19, 2018
Among several forms of pancreatic cancer, one of them specifically affects women, often young. How is this possible, even though the pancreas is an organ with little exposure to sex hormones? This pancreatic cancer, known ...

Mutant cells colonize our tissues over our lifetime

October 18, 2018
By the time we reach middle age, more than half of the oesophagus in healthy people has been taken over by cells carrying mutations in cancer genes, scientists have uncovered. By studying normal oesophagus tissue, scientists ...

Study involving hundreds of patient samples may reveal new treatment options of leukemia

October 17, 2018
After more than five years and 672 patient samples, an OHSU research team has published the largest cancer dataset of its kind for a form of leukemia. The study, "Functional Genomic Landscape of Acute Myeloid Leukemia", published ...

A 150-year-old drug might improve radiation therapy for cancer

October 17, 2018
A drug first identified 150 years ago and used as a smooth-muscle relaxant might make tumors more sensitive to radiation therapy, according to a recent study led by researchers at The Ohio State University Comprehensive Cancer ...

Loss of protein p53 helps cancer cells multiply in 'unfavourable' conditions

October 17, 2018
Researchers have discovered a novel consequence of loss of the tumour protein p53 that promotes cancer development, according to new findings in eLife.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.